Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Reilly Kobbe, Marta Salas, Noa Biran, David S. Siegel, Benjamin Tycko

Blood (2024) 144 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2024-209229

Published: 2024

Journal Articles

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Azra Raza, MD, Aref Al-Kali, MD, Raoul Tibes, MD PhD, Gary Spitzer, MD, Manila Gaddh, MD, Benjamin Tycko, MD PhD, Sangmin Lee, MD, Naomi Galili, PhD, Abdullah Mahmood Ali, PhD, John G. Mears, MD, Siddhartha Mukherjee, MD PhD, Ryan Shelton, BS, Steven M. Fruchtman, MD, Michael E. Petrone, MD MPH, Patrick S. Zbyszewski, MBA, Mark Lawrence Heaney, MD PhD

Blood (2017) 130 (Supplement 1): 1689.

https://doi.org/10.1182/blood.V130.Suppl_1.1689.1689

Published: 2017

Journal Articles

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Azra Raza, MD, Benjamin Tycko, M.D., Ph.D., Sangmin Lee, MD, Naomi Galili, Ph.D., Abdullah Ali, Andrew Eisenberger, MD, John G. Mears, MD, Aref Al-Kali, MD, Raoul Tibes, MD, PhD, Gary Spitzer, MD, Francois Wilhelm, MD, PhD., Siddhartha Mukherjee, MD, PhD

Blood (2013) 122 (21): 2745.

https://doi.org/10.1182/blood.V122.21.2745.2745

Published: 2013

Journal Articles

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer Amengual, Venkatraman E. Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis M. Temkin, Samir Parekh, Benjamin Tycko, Owen A. O'Connor

Blood (2011) 118 (20): 5506–5516.

https://doi.org/10.1182/blood-2011-02-336891

Published: 2011

Includes: Supplemental data

Journal Articles

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma

Matko Kalac, M.D., Ph.D., Enrica Marchi, M.D., Ph.D., Luigi Scotto, Ph.D., Jennifer Amengual, M.D., Venkatraman Seshan, Govind Bhagat, M.D., Netha Ulahannan, Violetta Leshchenko, Ph.D., Samir Parekh, M.D., Benjamin Tycko, M.D., Ph.D., Owen A. O'Connor, M.D., Ph.D.

Blood (2010) 116 (21): 435.

https://doi.org/10.1182/blood.V116.21.435.435

Published: 2010

Journal Articles

Histone Deacetylase Inhibitors Synergistically Enhance the Cytotoxic Effect of Hypomethylating Agents in Models of Diffuse Large B-Cell Lymphoma.

Matko Kalac, MD, Yukiko Kitagawa, MD, PhD, Seshan Ennapadam Venkatraman, Benjamin Tycko, MD, PhD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 3720.

https://doi.org/10.1182/blood.V114.22.3720.3720

Published: 2009

NARROW

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma

Histone Deacetylase Inhibitors Synergistically Enhance the Cytotoxic Effect of Hypomethylating Agents in Models of Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma

Histone Deacetylase Inhibitors Synergistically Enhance the Cytotoxic Effect of Hypomethylating Agents in Models of Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only